BridgeMD
New treatment option for COPD
Official title Bronchodilators and Lung Mechanics During Exercise in COPD
ClinicalTrials.gov ID: NCT06825013
What this study is testing
What is Bronchodilators inhalation?
Bronchodilators inhalation is an investigational medicine, given as a treatment applied to the skin, being studied as a potential treatment for copd.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Bronchodilators are medications that open the bronchi to help patients with COPD to breathe better. It is still not known exactly how this effect improves shortness of breath in people with COPD.
- Phase 4: studies an already-approved treatment
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 40 and older
You may be able to join if
- Diagnosis of COPD
- Male or female ≥40-years-of-age
- Current or former smokers with ≥20 pack-year history
- Forced expiratory volume in 1 second (FEV1)/ forced vital capacity (FVC)\<lower limit of normal
- Pre-Post Change of FVC ≥ 10% predicted after 400 mcg inhaled salbutamol
You likely can't join if
- Major cardiopulmonary diseases other than COPD (asthma, interstitial lung disease, pulmonary hypertension, and congestive heart failure)
- Neuromuscular or musculoskeletal disease
- Use of daytime oxygen or exercise induced O2 desaturation to \< 80% on room air;
- Any other disorder that may contribute to exertional dyspnoea and/or exercise intolerance
- Any contraindication to cardiopulmonary exercise testing
See the full eligibility criteria
- Diagnosis of COPD
- Male or female ≥40-years-of-age
- Current or former smokers with ≥20 pack-year history
- Forced expiratory volume in 1 second (FEV1)/ forced vital capacity (FVC)\<lower limit of normal
- Pre-Post Change of FVC ≥ 10% predicted after 400 mcg inhaled salbutamol
- Functional residual capacity ≥120%predicted and/or the upper limit of normal
- Modified Medical Research Council dyspnea scale ≥ 2
- Clinically stable as defined by no exacerbations in the preceding 6 weeks
- Ability to provide informed consent and perform all study procedures
- Major cardiopulmonary diseases other than COPD (asthma, interstitial lung disease, pulmonary hypertension, and congestive heart failure)
- Neuromuscular or musculoskeletal disease
- Use of daytime oxygen or exercise induced O2 desaturation to \< 80% on room air;
- Any other disorder that may contribute to exertional dyspnoea and/or exercise intolerance
- Any contraindication to cardiopulmonary exercise testing
The study team makes the final eligibility decision.
Where it's taking place
- Kingston, Ontario, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 40 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Kingston, Ontario, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.